News | April 03, 2026
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Subscribe To Our Newsletter & Stay Updated
